NCT06932952 - A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

September 30, 2027

Conditions

Solid Tumor

Interventions

DRUG

BYON4228 + Pembrolizumab

BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every three weeks until disease progression or unacceptable toxicity. Different doses. Pembrolizumab IV infusion (200 mg) every three weeks from the second treatment cycle onwards.

Trial Locations (6)

Unknown

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

UZ Leuven, Leuven

RECRUITING

CIOCC Hospital Universitario HM Sanchinarro, Madrid

RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

RECRUITING

The Christie NHS Foundation Trust, Manchester

RECRUITING

The Royal Marsden, Sutton